Bioavailability of IgG Administered by the Subcutaneous Route

PURPOSE: US licensing studies of subcutaneous IgG (SCIG) calculate dose adjustments necessary to achieve area under the curve (AUC) of serum IgG vs. time on SCIG that is non-inferior to that on intravenous IgG (IVIG), within the FDA-set limit of ±20 %. The results are interpreted as showing that dif...

Descripción completa

Detalles Bibliográficos
Autores principales: Berger, Melvin, Jolles, Stephen, Orange, Jordan S., Sleasman, John W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682093/
https://www.ncbi.nlm.nih.gov/pubmed/23456255
http://dx.doi.org/10.1007/s10875-013-9876-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682093/
https://www.ncbi.nlm.nih.gov/pubmed/23456255
http://dx.doi.org/10.1007/s10875-013-9876-3

Ejemplares similares